 | ||
| B*3508-β2MG with bound peptide | ||
| 2h6p | ||
major histocompatibility complex (human), class I, B35 | ||
| Alleles | B*3501, 3502, 3503, . . . | |
| Structure (See HLA-B) | ||
| Symbol(s) | HLA-B | 2fyy, 2fz3 |
| EBI-HLA | B*3501 | 2h6p, 2cik, 1a1n |
| EBI-HLA | B*3502 | |
| EBI-HLA | B*3503 | |
| EBI-HLA | B*3504 | |
| EBI-HLA | B*3505 | |
| EBI-HLA | B*3506 | |
| EBI-HLA | B*3507 | |
| EBI-HLA | B*3508 | 2nw3, 2nx5 |
| EBI-HLA | B*3509 | |
| EBI-HLA | B*3510 | |
| EBI-HLA | B*3511 | |
| EBI-HLA | B*3512 | |
| Locus | chr.6 6p21.31 | |
HLA-B35 (B35) is an HLA-B serotype. The serotype identifies the more common HLA-B*35 gene products.[1] B35 is one of the largest B serotype groups, it currently has 97 known nucleotide variants and 86 polypeptide isoforms. (For terminology help see: HLA-serotype tutorial). This variant is particularly susceptible to HIV infection.
Serotype
| B*35 | B35 | Sample | |
| allele | % | % | size (N) |
| 3501 | 98 | 2023 | |
| 3502 | 72 | 1013 | |
| 3503 | 94 | 1226 | |
| 3504 | 100 | 26 | |
| 3505 | 94 | 231 | |
| 3506 | 79 | 10 | |
| 3508 | 91 | 349 | |
| 3509 | 68 | 3 | |
| 3510 | 75 | 12 | |
| 3511 | 67 | 17 | |
| 3512 | 78 | 422 | |
| 3514 | 79 | 29 | |
| 3520 | 42 | 23 |
References
- ↑ Marsh, S. G.; Albert, E. D.; Bodmer, W. F.; Bontrop, R. E.; Dupont, B.; Erlich, H. A.; Fernández-Viña, M.; Geraghty, D. E.; Holdsworth, R.; Hurley, C. K.; Lau, M.; Lee, K. W.; Mach, B.; Maiers, M.; Mayr, W. R.; Müller, C. R.; Parham, P.; Petersdorf, E. W.; Sasazuki, T.; Strominger, J. L.; Svejgaard, A.; Terasaki, P. I.; Tiercy, J. M.; Trowsdale, J. (2010). "Nomenclature for factors of the HLA system, 2010". Tissue Antigens. 75 (4): 291–455. doi:10.1111/j.1399-0039.2010.01466.x. PMC 2848993. PMID 20356336.
- ↑ derived from IMGT/HLA
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.